Skip to main content
Figure 2 | BMC Musculoskeletal Disorders

Figure 2

From: Cannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritis

Figure 2

Inhibition of IL-6, MMP-3, and CCL2 production from FLS by the selective CB 2 agonist JWH133. CB2 expression on in vitro cultured FLS from three RA patients was detected with Western blotting analysis (A). Bars indicate 50 and 37 kDa. Predicted molecular weight of CB2 is 45 kDa. RA FLS were treated with various concentrations of JWH133, from 30 minutes before the stimulation with TNF-α for 24 h. Concentrations of IL-6 (B), MMP-3 (C), and CCL2 (D) in the cultured supernatants were measured with ELISA. Data is presented as means ± SEM of one of three independent experiments analyzed in quadruplicate. *p < 0.05, **p < 0.01.

Back to article page